A Profile of Gemifloxacin, a New Respiratory Fluoroquinolone

Today's Therapeutic Trends

Volumn 21, Issue 4, 2003, Pages 415-435

  File Jr , Thomas M ^a,b   Iannini, Paul B ^c,d  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b SUMMA HEALTH SYSTEM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DANBURY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BACTERIAL DNA; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACKACHE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DNA REPLICATION; DRUG ABSORPTION; DRUG COST; DRUG DOSE REGIMEN; DRUG POTENCY; DYSPEPSIA; FATIGUE; FLATULENCE; HEADACHE; HUMAN; HYPERGLYCEMIA; INJURY; INSOMNIA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYALGIA; NAUSEA; RASH; REVIEW; RHINITIS; SINUSITIS; URTICARIA; VERTIGO; VOMITING;

EID: 0242362709     PISSN: 07412320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Minino AM, Arias E, Kochanek KD, et al.: Deaths: Final Data for 2000. Natl. Vital Stat. Rep. 50:(15), 2002.
2. Mannino DM, Homa DM, Akinbami LJ, et al.: Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. Respir. Care 47:1184-1189, 2002.
3. Hall MJ and Owings MF: 2000 National Hospital Discharge Survey. Advance data from vital and health statistics (No. 329). National Center for Health Statistics, Hyattsville, MD, 2002.
4. Niederman MS, McCombs JS, Unger LN, et al.: The cost of treating community-acquired pneumonia. Clin. Ther. 20:820-837, 1998.
5. Niederman MS, McCombs JS, Unger AN, et al.: Treatment cost of acute exacerbations of chronic bronchitis. Clin. Ther. 21:576-591, 1999.
6. Jacobs MR, Felmingham D, Appelbaum PC and Grüneberg RN, for the Alexander Project Group: The Alexander Project 1998-2000: Susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 52:229-246, 2003.
7. Hong CY. Discovery of gemifloxacin (Factive, LB20304a): A quinolone of a new generation. Il Farmaco 56:41-44, 2001.
8. Hoban D, Biuchilon SK, Johnson JL, et al.: Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in North American surveillance study. Diagn. Microbiol. Infect. Dis. 40:51-57, 2001.
9. Koeth LM, Jacobs MR, Bjajaksouzian S, et al.: Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000. Int. J. Antimicrob. Agents 19:33-37, 2002.
10. Jones RN and Biedenbach D: Comparative activity of garenoxacin (BMS 284756), a novel des-fluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001) Diagn. Microbiol. Infect. Dis. 45:273-278, 2003.
11. Biedenbach D and Jones RN: Five year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: Prevalence results from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 46:55-61, 2003.
12. Dubois J and St-Pierre G: Comparative in vitro activity and post antibiotic effect of gemifloxacin against Legionella species. J. Antimicrob. Chemother. 45(Suppl. 1):41-46, 2000.
13. Roblin PM, Reznik T, Kutlin A and Hammerschlag MR: In vitro activities of gemifloxacin (SB265805, LB20304a) against recent clinical isolates of Chlamydia pneumoniae. Antimicrob. Agents Chemother. 43:2806-2807, 1999.
14. Waites KB, Crabb DM and Duffy LB: Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae. Int. J. Antimicrob. Agents 21:574-577, 2003.
15. Heaton VJ, Goldsmith CE, Ambler JE and Fisher LM: Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms. Antimicrob. Agents Chemother. 43:2998-3000, 1999.
16. Heaton VJ, Ambler JE and Fisher LM: Potent and pneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob. Agents Chemother. 44:3112-3117, 2000.
17. Morrissey I and George JT: Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones. J. Antimicrob. Chemother. 45(Suppl. 1):101-106, 2000.
18. Pérez-Trallero E, García-Rey C, Martín-Sá nchez AM, et al.: Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain. Antimicrob. Agents Chemother. 46:2665-2667, 2002.
19. Garcia-Olmos M, Parra A, Garcia-Calvo G, et al.: Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility. Int. J. Antimicrob. Agents 21(6):568-573, 2003.
20. Allen A, Bygate E, Vousden M, et al.: Multiple dose pharmacokinetics and tolerability of gemifloxacin administered to healthy volunteers. Antimcrob. Agents Chemother. 45:540-545, 2001.
21. Gemifloxacin (Factive®) package insert, July 2003. Genesoft Pharmaceuticals, South San Franciscso, CA.
22. Allen A, Bygate E, Clark D, et al.: The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers. Int. J. Antimicrob. Agents 16:45-50, 2000.
23. Allen A, Bygate E, Faessal H, et al.: The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers. Int. J. Antimicrob. Agents 15:283-289, 2000.
24. Soman A, Honeybourne D, Andrews J, et al.: Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 44(6):835-838, 1999.
25. Gatifloxacin (Tequin®) package insert, 2002. Bristol-Myers Squibb Company, Princeton, NJ.
26. Levofloxacin (Levaquin®) package insert, 2002. Ortho-McNeil Pharmaceuticals, Raritan, NJ.
27. Ciprofloxacin (Cipro®) package insert, 2002. Bayer Pharmaceuticals, West Haven, CT.
28. Ball P, File TM Jr, Twynholm M and Henkle T: Efficacy and safety of gemifloxacin 320 mg once daily for 7 days in the treatment of adult lower respiratory tract infections. Int. J. Antimicrob. Agents 18:19-27, 2001.
29. Wilson R, Schentag JJ, Ball P and Mandell LA: A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long term clinical outcomes. Clin. Ther. 24:639-652, 2002.
30. Halpern MT, Palmer CS, Zodet M and Kirsch J: Cost-effectiveness of gemifloxacin: Results from the GLOBE study. Am. J. Health Syst. Pharm. 59(14):1357-1365, 2002.
31. Spencer S and Jones PW: Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 58:589-593, 2003.
32. Wilson R, Langan C, Ball P, et al.: Oral gemifloxacin once daily for 5 days compared with sequential therapy with iv ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir. Med. 97:242-249, 2003.
33. Lode H, File TM Jr, Mandell LA, et al.: Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: A randomized, open-label, multicenter study of clinical efficacy. Clin. Ther. 24:1915-1936, 2002.
34. File TM Jr, Sclemmer B, Garau J, et al.: Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: A randomized, double-blind comparison with trovafloxacin. J. Antimicrob. Chemother. 48:67-74, 2001.
35. Ball P, Mandell L, Niki Y and Tillotson G: Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf. 21(5):407-421, 1999.